Bibliography
- Hawkins PT, Anderson KE, Davidson K, Stephens LR. Signalling through Class I PI3Ks in mammalian cells. Biochem Soc Trans 2006;34(Pt 5):647-62
- Vanhaesebroeck B, Waterfield MD. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 1999;253(1):239-54
- Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 2010;11:329-41
- Fung-Leung WP. Phosphoinositide 3-kinase delta (PI3Kdelta) in leukocyte signaling and function. Cell Signal 2011;23(4):603-8
- Norman P. Selective PI3Kdelta inhibitors, a review of the patent literature. Expert Opin Ther Pat 2011;21(11):1773-90
- Sadhu C, Dick K, Tino WT, Staunton DE. Selective role of PI3K delta in neutrophil inflammatory responses. Biochem Biophys Res Commun 2003;308(4):764-9
- Macias-Perez IM, Flinn IW. GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemia. Curr Hematol Malig Rep 2013;8(1):22-7
- FDA news release, FDA approves Zydelig for three types of blood cancers. 2014. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm406387.htm
- Shugg RP, Thomson A, Tanabe N, et al. Effects of isoform-selective phosphatidylinositol 3-kinase inhibitors on osteoclasts: actions on cytoskeletal organization, survival, and resorption. J Biol Chem 2013;288(49):35346-57
- Winkler DG, Faia KL, DiNitto JP, et al. PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol 2013;20(11):1364-74
- Lanasa MC, Glenn M, Mato AR, et al. First-in-human study of AMG 319, a highly selective, small molecule inhibitor of PI3Kdelta, in adult patients with relapsed or refractory lymphoid malignancies. 55th ASH Annual Meeting and Exposition, New Orleans; 7 – 10 December 2013; abstract 678
- Sriskantharajah S, Hamblin N, Worsley S, et al. Targeting phosphoinositide 3-kinase delta for the treatment of respiratory diseases. Ann N Y Acad Sci 2013;1280:35-9
- Kizawa Y, Kimura G, Ueda K, Ito K. Effects of RV1729, a phosphoinositide-3-kinase delta and gamma inhibitor, on steroid insensitive airway inflammation in tobacco-smoke and allergen challenged mice. American Thoracic Society, Philadelphia; May 2013; A3878, 10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A3878
- Norman P. Evaluation of WO2013136076: two crystalline forms of the phosphatidylinositol 3-kinase-delta inhibitor RV-1729. Expert Opin Ther Pat 2014;24(4):471-5
- Safina BS, Sweeney ZK, Li J, et al. Identification of GNE-293, a potent and selective PI3Kdelta inhibitor: navigating in vitro genotoxicity while improving potency and selectivity. Bioorg Med Chem Lett 2013;23(17):4953-9
- Haselmayer P, Camps M, Muzerelle M, et al. Characterization of novel PI3Kdelta inhibitors as potential therapeutics for SLE and lupus nephritis in pre-clinical studies. Front Immunol 2014;5:233
- Mattheakis L Kearney P, Jaeger C, et al. PI3Kdelta: discovery of potent and selective inhibitors for treating hematopoietic malignancies. 22nd EORTC-NCI-AACR symposium on “Molecular targets and Cancer Therapeutics”, Berlin, Germany; 2010. P 219
- Exelixis, Inc. Inhibitors of PI3K-delta and methods of their use and manufacture. WO037204;2012
- Exelixis, Inc. Inhibitors of PI3K-delta and methods of their use and manufacture. WO037226; 2012
- Norman P. Evaluation of WO2012037204 and WO2012037226: Exelixis’ selective PI3Kdelta inhibitors; the basis of a US$251 million deal. Expert Opin Ther Pat 2012.22(8):971-6
- Merck & Co. Exelixis Licenses PI3K-Delta Program to MerckPress. Release 21 December 2011 Available from: https://www.merck.com/licensing/our-partnership/Exelixis-licenses%20PI3K-partnership.html
- Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta. WO 075392;2014
- Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta. WO 075393;2014
- Hoffmann-La F, Roche AG. Purine compounds selective for PI3K p110 delta, and methods of use. WO007493; 2012
- Safina BS, Baker S, Baumgardner M, et al. Discovery of novel PI3-kinase delta specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition. J Med Chem 2012;55(12):5887-900